<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EN" hierarchy="1" humanitarian="4" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>GB-GOV-13-FUND--GCRF-MR_P001351_1</iati-identifier>
  <reporting-org ref="10" type="DEPARTMENT OF BUSINESS, ENERGY AND INDUSTRIAL STRATEGY">
   <narrative xml:lang="EN">1</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Enabling rapid conversion of antigen to vaccine, applied to multi-stage malaria vaccination</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">4</narrative>
  </description>
  <description type="1">
   <narrative xml:lang="EN">Vaccination is one of the most cost-effective ways to save lives and improve health. Despite the great success-stories of many human and animal vaccines, we still lack effective vaccines against major global killers such as malaria, tuberculosis and HIV. New vaccines are often developed from Virus-like particles (VLPs). VLPs resemble viruses in their size and shape, but carry no pathogenic genetic material and so do not cause disease. VLPs can be engineered to display a protein from a pathogen on their surface, to create an effective and safe vaccine. Decorating VLPs with such proteins from pathogens is one of the central challenges in the field of vaccine development, requiring expensive trial-and-error experiments and taking months to years. We have validated initial steps to overcome this key challenge. We engineered a &quot;bacterial superglue&quot; so that decorating VLPs simply requires mixing the VLP with the pathogenic protein. This attachment is fast, irreversible and broadly applicable. Due to the ease of the process, we have termed this platform Plug-and-Display vaccination. The pathogenic proteins we have focused on attaching to VLPs come from the malaria parasite. Malaria is one of the largest global health challenges, each year infecting approximately two million people and killing half a million people. With the difficulty in distributing effective drugs and the increase in drug resistance, there is urgent need to develop a malaria vaccine. We have investigated proteins on the surface of the malaria parasite at different stages of its life cycle and established key targets that could help create a more effective vaccine. In this proposal we will advance the Plug-and-Display vaccination approach in several ways, to maximise the immune responses to these malarial proteins. We will establish the use of our bacterial superglue for decoration of a different kind of VLP frequently used in the clinic. We will create new VLPs able to display three times more copies of the malarial protein, since that could stimulate an even stronger immune response. Also, VLPs will be precisely decorated with two different malarial proteins, to help generate a vaccine effective against a wider range of malaria strains. Since our Plug-and-Display VLPs could be useful not just for malaria but for a range of human and animal diseases, we will also increase the scale and stability of VLPs we produce, so that they can be a general resource for scientists worldwide and speed up the creation of effective vaccines against major health challenges.</narrative>
  </description>
  <other-identifier type="GB-GOV-13"></other-identifier>
  <activity-status code="2016-11-01"></activity-status>
  <activity-date iso-date="2016-12-01" type="2"></activity-date>
  <activity-date iso-date="2019-10-31" type="3"></activity-date>
  <activity-date iso-date="2020-01-13" type="4"></activity-date>
  <activity-date iso-date="KE" type="KENYA"></activity-date>
  <contact-info type="UK RESEARCH &amp; INNOVATION">
   <organisation>
    <narrative xml:lang="EN">International Development</narrative>
   </organisation>
   <department>
    <narrative xml:lang="EN">GCRF</narrative>
   </department>
   <person-name>
    <narrative xml:lang="EN">gcrf@ukri.org</narrative>
   </person-name>
   <email>https://www.ukri.org/</email>
   <website>Polaris House, Swindon, SN2 1LF</website>
   <mailing-address>
    <narrative xml:lang="EN">GBP</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="EASTERN AFRICA, REGIONAL" percentage="100">
   <narrative xml:lang="EN">1027</narrative>
  </recipient-country>
  <recipient-region code="1" percentage="100" vocabulary="RESEARCH/SCIENTIFIC INSTITUTIONS"></recipient-region>
  <sector percentage="100" vocabulary="1">
   <narrative xml:lang="EN">43082</narrative>
  </sector>
  <collaboration-type code="10"></collaboration-type>
  <default-flow-type code="110"></default-flow-type>
  <default-finance-type code="D02"></default-finance-type>
  <default-aid-type code="5" vocabulary="1"></default-aid-type>
  <budget status="2" type="1">
   <period-start iso-date="2016-04-01"></period-start>
   <period-end iso-date="2016-03-31"></period-end>
   <value currency="GBP" value-date="2016-08-08">61169.61</value>
  </budget>
  <budget status="2" type="1">
   <period-start iso-date="2017-04-01"></period-start>
   <period-end iso-date="2017-03-31"></period-end>
   <value currency="GBP" value-date="2016-08-08">245173.92</value>
  </budget>
  <budget status="2" type="1">
   <period-start iso-date="2018-04-01"></period-start>
   <period-end iso-date="2018-03-31"></period-end>
   <value currency="GBP" value-date="2016-08-08">247159.84</value>
  </budget>
  <budget status="2" type="1">
   <period-start iso-date="2019-04-01"></period-start>
   <period-end iso-date="2019-03-31"></period-end>
   <value currency="GBP" value-date="2016-08-08">124329.14</value>
  </budget>
  <capital-spend percentage="Our overall goal is to accelerate the generation of vaccines.  We aim to establish a modular generic platform, to make possible the rapid assembly of highly immunogenic virus-like particles (VLPs).   Specific objectives are: Objective 5: Establish large-scale high-grade production of SpyCatcher-VLPs. Having created a novel vaccine platform, through irreversible interaction of SpyTag-antigen with SpyCatcher-VLPs, we will optimise the production at large-scale with suitable stability and purity. This will be a key step to advance &quot;Plug-and-display immunisation&quot; as a general resource for the research community and towards clinical use against diverse human and animal health challenges.  Objective 3: Demonstrate SpyCatcher-VLPs based on a second, clinically-relevant carrier platform: Hepatitis B surface antigen. Our initial platform is based on the simply-expressed bacteriophage AP205. Plug-and-display vaccination using HBsAg will establish generality of the SpyCatcher approach, facilitate future manufacture, and determine the significance of AP205 for strong antibody responses after only a single injection.  Objective 1: Establishment of tunable and ultra-high density antigen display on VLPs for maximal antibody induction.  Conventional approaches quickly run into folding and expression blocks when multimerising antigens. The modular SpyCatcher approach will allow us to array 2 or 3 antigen copies on each subunit monomer of the capsid. We will focus on malarial blood-stage antigens for preventing red blood cell invasion. We can then investigate a fundamental question in vaccine development, as to how the level of multimerisation on VLPs determines generation of protective immune responses.  Objective 2: Establish dual plug-and-display immunisation, with modular covalent coupling of 2 different antigens to the same VLP. Combining SpyTag/SpyCatcher with our newly established SnoopTag/SnoopCatcher pair, we will achieve controlled and irreversible coupling of two different antigens to VLPs. We will test different nanoassemblies to optimise strong responses to both antigens. This approach should also enable quick screening for antigens able to give synergistic protection from malaria invasion of RBCs.  Objective 4: Establish the importance of immunity to the SpyCatcher-VLP platform, comparing distinct immunogens at prime versus boost.  An often neglected issue in vaccine research is the response to the platform rather than the candidate antigen. We will minimise SpyCatcher immunogenicity and explore different reactive modules for prime versus boost, thereby maximising the protective response from our novel VLP platforms."></capital-spend>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-01-01"></transaction-date>
   <value currency="GBP" value-date="2016/17 FY Q4">61169.61</value>
   <description>
    <narrative xml:lang="EN">Quarterly Payment for the GCRF funded activity</narrative>
   </description>
   <provider-org provider-activity-id="GB-GOV-13-FUND--GCRF-MR_P001351_1" ref="GB-GOV-13">
    <narrative xml:lang="EN">UK - Department for Business, Energy and Industrial Strategy</narrative>
   </provider-org>
   <receiver-org ref="GB-UKPRN-10007774">
    <narrative xml:lang="EN">University of Oxford</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-04-01"></transaction-date>
   <value currency="GBP" value-date="2017/18 FY Q1">61169.61</value>
   <description>
    <narrative xml:lang="EN">Quarterly Payment for the GCRF funded activity</narrative>
   </description>
   <provider-org provider-activity-id="GB-GOV-13-FUND--GCRF-MR_P001351_1" ref="GB-GOV-13">
    <narrative xml:lang="EN">UK - Department for Business, Energy and Industrial Strategy</narrative>
   </provider-org>
   <receiver-org ref="GB-UKPRN-10007774">
    <narrative xml:lang="EN">University of Oxford</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-07-01"></transaction-date>
   <value currency="GBP" value-date="2017/18 FY Q2">61169.61</value>
   <description>
    <narrative xml:lang="EN">Quarterly Payment for the GCRF funded activity</narrative>
   </description>
   <provider-org provider-activity-id="GB-GOV-13-FUND--GCRF-MR_P001351_1" ref="GB-GOV-13">
    <narrative xml:lang="EN">UK - Department for Business, Energy and Industrial Strategy</narrative>
   </provider-org>
   <receiver-org ref="GB-UKPRN-10007774">
    <narrative xml:lang="EN">University of Oxford</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-10-01"></transaction-date>
   <value currency="GBP" value-date="2017/18 FY Q3">61169.61</value>
   <description>
    <narrative xml:lang="EN">Quarterly Payment for the GCRF funded activity</narrative>
   </description>
   <provider-org provider-activity-id="GB-GOV-13-FUND--GCRF-MR_P001351_1" ref="GB-GOV-13">
    <narrative xml:lang="EN">UK - Department for Business, Energy and Industrial Strategy</narrative>
   </provider-org>
   <receiver-org ref="GB-UKPRN-10007774">
    <narrative xml:lang="EN">University of Oxford</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-01-01"></transaction-date>
   <value currency="GBP" value-date="2017/18 FY Q4">61665.09</value>
   <description>
    <narrative xml:lang="EN">Quarterly Payment for the GCRF funded activity</narrative>
   </description>
   <provider-org provider-activity-id="GB-GOV-13-FUND--GCRF-MR_P001351_1" ref="GB-GOV-13">
    <narrative xml:lang="EN">UK - Department for Business, Energy and Industrial Strategy</narrative>
   </provider-org>
   <receiver-org ref="GB-UKPRN-10007774">
    <narrative xml:lang="EN">University of Oxford</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-04-01"></transaction-date>
   <value currency="GBP" value-date="2018/19 FY Q1">61665.09</value>
   <description>
    <narrative xml:lang="EN">Quarterly Payment for the GCRF funded activity</narrative>
   </description>
   <provider-org provider-activity-id="GB-GOV-13-FUND--GCRF-MR_P001351_1" ref="GB-GOV-13">
    <narrative xml:lang="EN">UK - Department for Business, Energy and Industrial Strategy</narrative>
   </provider-org>
   <receiver-org ref="GB-UKPRN-10007774">
    <narrative xml:lang="EN">University of Oxford</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-07-01"></transaction-date>
   <value currency="GBP" value-date="2018/19 FY Q2">61665.09</value>
   <description>
    <narrative xml:lang="EN">Quarterly Payment for the GCRF funded activity</narrative>
   </description>
   <provider-org provider-activity-id="GB-GOV-13-FUND--GCRF-MR_P001351_1" ref="GB-GOV-13">
    <narrative xml:lang="EN">UK - Department for Business, Energy and Industrial Strategy</narrative>
   </provider-org>
   <receiver-org ref="GB-UKPRN-10007774">
    <narrative xml:lang="EN">University of Oxford</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-10-01"></transaction-date>
   <value currency="GBP" value-date="2018/19 FY Q3">61665.09</value>
   <description>
    <narrative xml:lang="EN">Quarterly Payment for the GCRF funded activity</narrative>
   </description>
   <provider-org provider-activity-id="GB-GOV-13-FUND--GCRF-MR_P001351_1" ref="GB-GOV-13">
    <narrative xml:lang="EN">UK - Department for Business, Energy and Industrial Strategy</narrative>
   </provider-org>
   <receiver-org ref="GB-UKPRN-10007774">
    <narrative xml:lang="EN">University of Oxford</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-01-01"></transaction-date>
   <value currency="GBP" value-date="2018/19 FY Q4">62164.57</value>
   <description>
    <narrative xml:lang="EN">Quarterly Payment for the GCRF funded activity</narrative>
   </description>
   <provider-org provider-activity-id="GB-GOV-13-FUND--GCRF-MR_P001351_1" ref="GB-GOV-13">
    <narrative xml:lang="EN">UK - Department for Business, Energy and Industrial Strategy</narrative>
   </provider-org>
   <receiver-org ref="GB-UKPRN-10007774">
    <narrative xml:lang="EN">University of Oxford</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-04-01"></transaction-date>
   <value currency="GBP" value-date="2019/20 FY Q1">62164.57</value>
   <description>
    <narrative xml:lang="EN">Quarterly Payment for the GCRF funded activity</narrative>
   </description>
   <provider-org provider-activity-id="GB-GOV-13-FUND--GCRF-MR_P001351_1" ref="GB-GOV-13">
    <narrative xml:lang="EN">UK - Department for Business, Energy and Industrial Strategy</narrative>
   </provider-org>
   <receiver-org ref="GB-UKPRN-10007774">
    <narrative xml:lang="EN">University of Oxford</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-07-01"></transaction-date>
   <value currency="GBP" value-date="2019/20 FY Q2">62164.57</value>
   <description>
    <narrative xml:lang="EN">Quarterly Payment for the GCRF funded activity</narrative>
   </description>
   <provider-org provider-activity-id="GB-GOV-13-FUND--GCRF-MR_P001351_1" ref="GB-GOV-13">
    <narrative xml:lang="EN">UK - Department for Business, Energy and Industrial Strategy</narrative>
   </provider-org>
   <receiver-org ref="GB-UKPRN-10007774">
    <narrative xml:lang="EN">University of Oxford</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-04-01"></transaction-date>
   <value currency="GBP" value-date="2020/21 FY Q1">62074.46</value>
   <description>
    <narrative xml:lang="EN">Quarterly Payment for the GCRF funded activity</narrative>
   </description>
   <provider-org provider-activity-id="GB-GOV-13-FUND--GCRF-MR_P001351_1" ref="GB-GOV-13">
    <narrative xml:lang="EN">UK - Department for Business, Energy and Industrial Strategy</narrative>
   </provider-org>
   <receiver-org ref="GB-UKPRN-10007774">
    <narrative xml:lang="EN">University of Oxford</narrative>
   </receiver-org>
  </transaction>
  <document-link format="HTTPS://WWW.UKRI.ORG/FUNDING/INFORMATION-FOR-AWARD-HOLDERS/GRANT-TERMS-AND-CONDITIONS/" url="A04">
   <title>
    <narrative xml:lang="EN">application/pdf</narrative>
   </title>
   <category code="0"></category>
  </document-link>
  <conditions attached="UK Research &amp; Innovation Grant Terms and Conditions"></conditions>
  <iati-activities>
   <iati-activity>
    <title>
     <narrative xml:lang="2021-09-24"></narrative>
    </title>
   </iati-activity>
  </iati-activities>
 </iati-activity>
</iati-activities>
